Cardiac Imaging in the VALOR-HCM Trial

Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals

Contenuto fornito da Cleveland Clinic Heart & Vascular Institute, Cleveland Clinic Heart, and Vascular Institute. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Cleveland Clinic Heart & Vascular Institute, Cleveland Clinic Heart, and Vascular Institute o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

4M ago 31:28

MP3•Pagina principale dell'episodio

Mavacamten is the first and only FDA-approved cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (HCM). An important factor to the success of the VALOR HCM trial was the participation of specialized cardiac sonographers and imagers.
Milind Desai, MD, MBA speaks with Jeanne Drinko, Amy Kanta and Anne Campbell about the importance of cardiac imaging.
Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research
Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162

310 episodi

#Fitness #Cardiac Consult: For Healthcare Professionals #Cleveland Clinic #Vascular Institute #Cleveland Clinic Heart #Health Industry #Health and Well-Being #Health Care